End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
0.8925 USD | -2.25% | +6.25% | -96.71% |
Apr. 19 | Sunshine Biopharma Unit Receives Health Canada Approval for Biosimilar Product | MT |
Apr. 19 | Top Premarket Decliners | MT |
Financials (USD)
Sales 2024 * | 44.4M | Sales 2025 * | 100M | Capitalization | 888K |
---|---|---|---|---|---|
Net income 2024 * | - | Net income 2025 * | 12M | EV / Sales 2024 * | 0.02 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 0.01 x |
P/E ratio 2024 * |
1.16
x | P/E ratio 2025 * |
0.09
x | Employees | 44 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 90.55% |
1 day | -2.25% | ||
1 week | +6.25% | ||
Current month | +2.00% | ||
1 month | -90.90% | ||
3 months | -95.85% | ||
6 months | -96.91% | ||
Current year | -96.71% |
Managers | Title | Age | Since |
---|---|---|---|
Steve Slilaty
CEO | Chief Executive Officer | 71 | 09-10-14 |
Camille Sebaaly
DFI | Director of Finance/CFO | 62 | 09-10-14 |
Marc Beaudoin
COO | Chief Operating Officer | - | Jan. 24 |
Members of the board | Title | Age | Since |
---|---|---|---|
David Natan
BRD | Director/Board Member | 70 | 22-01-31 |
Steve Slilaty
CEO | Chief Executive Officer | 71 | 09-10-14 |
Camille Sebaaly
DFI | Director of Finance/CFO | 62 | 09-10-14 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-10 | 0.8925 | -2.25% | 1,689,144 |
24-05-09 | 0.913 | -7.78% | 1,955,044 |
24-05-08 | 0.99 | -2.94% | 3,261,749 |
24-05-07 | 1.02 | +3.06% | 6,552,095 |
24-05-06 | 0.9897 | +17.82% | 15,306,016 |
End-of-day quote Nasdaq, May 09, 2024
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-96.71% | 888K | |
+30.38% | 684B | |
+26.51% | 568B | |
-4.36% | 361B | |
+19.30% | 329B | |
+3.73% | 284B | |
+16.70% | 240B | |
+8.78% | 208B | |
-7.93% | 200B | |
+7.68% | 166B |
- Stock Market
- Equities
- SBFM Stock